Concert Pharma (CNCE) Reports Q3 EPS of $5.44

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of $5.44, versus ($0.51) reported last year. Revenue for the quarter came in at $143.8 million versus the consensus estimate of $11.7 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance